GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05686551 |
Recruitment Status :
Recruiting
First Posted : January 17, 2023
Last Update Posted : April 29, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Huntington Disease | Drug: Tominersen 60 mg Drug: Placebo Drug: Tominersen 100 mg | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease |
Actual Study Start Date : | February 3, 2023 |
Estimated Primary Completion Date : | February 28, 2026 |
Estimated Study Completion Date : | April 1, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Tominersen 60 mg |
Drug: Tominersen 60 mg
60 mg tominersen administered intrathecally every 16 weeks |
Placebo Comparator: Placebo |
Drug: Placebo
Matching placebo administered intrathecally every 16 weeks |
Experimental: Tominersen 100 mg |
Drug: Tominersen 100 mg
100 mg tominersen administered intrathecally every 16 weeks |
- Incidence and severity of adverse events, with severity determined according to the Adverse Event Severity Grading Scale [ Time Frame: Up to Approximately 24 Months ]
- Change from baseline in clinical laboratory results - Cerebrospinal fluid (CSF) White Blood Cell (WBC) (1/uL) [ Time Frame: From Baseline Visit (Day 1), and Months 4, 8, 9, 12, 16 ]
- Change from baseline in clinical laboratory results Cerebrospinal fluid (CSF) protein (g/L) [ Time Frame: From Baseline Visit (Day 1), and Months 4, 8, 9, 12, 16 ]
- Change in baseline in structural MRI assessing any new abnormalities including radiographic features consistent with hydrocephalus and other relevant MRI safety findings [ Time Frame: From Baseline, Months 4, 8, 12, 16 and Up to Approximately Month 24 ]
- Percentage change from baseline in geometric means of CSF mHTT protein levels at Month 9 [ Time Frame: Baseline and Month 9 ]
- Change from baseline in composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores (non-U.S. sites) at 16 months [ Time Frame: Baseline to 16 Months ]Change in scores on the scale
- Change from baseline in Total Functional Capacity (TFC) Scores (U.S. sites) at 16 months [ Time Frame: Baseline to 16 Months ]Change in scores on the scale
- Change from baseline in MoCA Scores [ Time Frame: From Baseline, Months 4, 8, 12, 16 and up to approximately Month 24 ]
- Percentage of participants with suicidal ideation or behavior as assessed by C-SSRS score at each visit, including detailed focus on any individual cases identified as having severe ideation or behavior during the study conduct [ Time Frame: Up to Approximately 24 Months ]
- Change from baseline at 16 months for the assessments of TFC (non-U.S. sites) Scores [ Time Frame: Baseline to 16 Months ]
- Change from baseline at 16 months for the assessments of cUHDRS (U.S. sites) Scores [ Time Frame: Baseline to 16 Months ]
- Change from baseline at 16 months for the assessments of Symbol Digit Modalities Test (SDMT) Scores [ Time Frame: Baseline to 16 Months ]
- Change from Baseline at 16 Months for the Assessments of Stroop Word Reading (SWR) Scores [ Time Frame: Baseline to 16 Months ]
- Change from baseline at 16 months for the assessments of Total Motor Score (TMS) [ Time Frame: Baseline to 16 Months ]
- Change from baseline in CSF Neurofilament light Chain (NfL) levels at 16 months [ Time Frame: Baseline to 16 Months ]
- Incidence of anti-drug antibodies (ADAs) at specified timepoints relative to the prevalence of ADAs at baseline [ Time Frame: From Baseline, Months 4, 8, 12, 16 and Up to Approximately Month 24 ]
- Titers determined if ADAs are identified [ Time Frame: From Baseline, Months 4, 8, 12, 16 and Up to Approximately Month 24 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria
-Huntington's disease (HD) gene expansion mutation carrier status with a CAP score of 400-500 inclusive
Either:
- Prodromal HD (defined as DCL 2 to 3, Independence Scale (IS) ⩾70, and ⩾TFC8); or
- Early manifest HD (defined as DCL 4, Independence Scale (IS) ⩾70, and ⩾TFC8);
- Total body weight > 40 kg and a body mass index within the range of 18-32 kg/m2
- Study Companion
Key Exclusion Criteria
- Current or previous use of an ASO (including small interfering RNA) or any HTT lowering therapy (including tominersen)
- Anti-platelet or anticoagulant therapy within 14 days prior to screening or anticipated use during the study, including, but not limited to, aspirin (unless </= 81 mg/day), clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban, apixaban, and heparin
- History of gene therapy, cell transplantation, or brain surgery
- Hydrocephalus
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 5 months after the final dose of study drug
- History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that required hospital visit and/or change in level of care within 12 months prior to screening
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05686551
Contact: Reference Study ID Number: BN42489 https://forpatients.roche.com/ | 888-662-6728 (U.S. Only) | global-roche-genentech-trials@gene.com |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT05686551 |
Other Study ID Numbers: |
BN42489 Other ( Other Identifier: GENERATION HD2 ) |
First Posted: | January 17, 2023 Key Record Dates |
Last Update Posted: | April 29, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm). |
Supporting Materials: |
Study Protocol |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Prodromal and Early Manifest Huntington's Disease |
Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Dementia Chorea Dyskinesias |
Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Cognition Disorders Neurocognitive Disorders Mental Disorders |